AR and prostate carcinoma: Androgen ablation, through suppression of androgen biosynthesis and/or antagonism of AR activity, initially induces apoptosis in a subset of prostate cancer cells and suppresses growth and proliferation in those that survive, which is evidenced by tumor regression and subsequent regrowth [5,9–12].